Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
Analyst Ratings
This is a breakdown of current ratings and price targets for Lucid Diagnostics and Akebia Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 1 | 0 | 4 | 0 | 2.60 |
| Akebia Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
Lucid Diagnostics presently has a consensus price target of $4.19, suggesting a potential upside of 904.20%. Akebia Therapeutics has a consensus price target of $3.90, suggesting a potential upside of 628.97%. Given Lucid Diagnostics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Lucid Diagnostics is more favorable than Akebia Therapeutics.
Insider and Institutional Ownership
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 6.9% of Lucid Diagnostics shares are owned by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Lucid Diagnostics and Akebia Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -959.76% | N/A | -119.57% |
| Akebia Therapeutics | -22.60% | -145.58% | -11.37% |
Valuation & Earnings
This table compares Lucid Diagnostics and Akebia Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $5.45 million | 15.57 | -$58.01 million | ($0.47) | -0.89 |
| Akebia Therapeutics | $236.20 million | 0.63 | -$5.34 million | ($0.16) | -3.34 |
Akebia Therapeutics has higher revenue and earnings than Lucid Diagnostics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Lucid Diagnostics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.
Summary
Lucid Diagnostics beats Akebia Therapeutics on 8 of the 13 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
